A positive Scientific Opinion
for remdesivir in the treatment of COVID-19 has been published by the Medicines
and Healthcare Products Regulatory products Agency (MHRA). It advises on the conditions where the technology
will be used and commissioned by the NHS.
Hospitals who have registered
an interest in participating in COVID-19 Early Access to Medicines Scheme
(EAMS) should use the country specific EAMS application process to apply for
access to remdesivir for eligible patients.
This alert provides information on medicine supply, access criteria, data collection and implementation.
Updated alert pdf attached to reflect an amendment to the second bullet point in the 'Illness severity and organ support criteria' section.